{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:42:58Z","timestamp":1791434578598,"version":"4.3.3"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejps.2019.105095","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T13:31:34Z","timestamp":1571146294000},"page":"105095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis"],"prefix":"10.1016","volume":"141","author":[{"given":"Mojca Kerec","family":"Kos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Miksi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Jovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-9117","authenticated-orcid":false,"given":"Robert","family":"Ro\u0161kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160tefan","family":"Grosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iztok","family":"Grabnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/archdischild-2013-305720","article-title":"Inter-individual variation in midazolam clearance in children","volume":"100","author":"Altamimi","year":"2015","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0003","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1460-9592.2010.03364.x","article-title":"A maturation model for midazolam clearance","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr Anaesth"},{"issue":"2","key":"10.1016\/j.ejps.2019.105095_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1734-1140(13)70969-1","article-title":"Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children","volume":"65","author":"Bienert","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-199835010-00003","article-title":"Clinical pharmacology of midazolam in infants and children","volume":"35","author":"Blumer","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ejps.2019.105095_bib0007","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.13459","article-title":"Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure","volume":"84","author":"Brussee","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"6 Pt 1","key":"10.1016\/j.ejps.2019.105095_bib0008","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.1994.186","article-title":"Population pharmacokinetics of midazolam in neonates","volume":"56","author":"Burtin","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0009","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2012.04206.x","article-title":"Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models","volume":"74","author":"Cella","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2019.105095_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","article-title":"The role of population pk-pd modelling in paediatric clinical research","volume":"67","author":"De Cock","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejps.2019.105095_bib0011","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: ontogeny and drug disposition","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ejps.2019.105095_bib0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/pgs.12.202","article-title":"CYP3A4 intron 6 c>t snp (CYP3A4\u00d722) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2019.105095_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2431-13-59","article-title":"A systematic review and meta-analysis to revise the fenton growth chart for preterm infants","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr"},{"issue":"10","key":"10.1016\/j.ejps.2019.105095_bib0014","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.ejps.2019.105095_bib0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bcp.13160","article-title":"Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?","volume":"83","author":"Germovsek","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ejps.2019.105095_bib0016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/BF02026712","article-title":"Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit","volume":"150","author":"Hartwig","year":"1991","journal-title":"Eur J Pediatr"},{"issue":"6","key":"10.1016\/j.ejps.2019.105095_bib0017","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bja\/79.6.740","article-title":"I.v. fentanyl decreases the clearance of midazolam","volume":"79","author":"Hase","year":"1997","journal-title":"Br J Anaesth"},{"issue":"9","key":"10.1016\/j.ejps.2019.105095_bib0018","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.ejps.2019.105095_bib0019","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the foce method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/106002809603000104","article-title":"Steady-state plasma concentrations of midazolam in critically ill infants and children","volume":"30","author":"Hughes","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.ejps.2019.105095_bib0021","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FTD.0b013e31825a4c3a","article-title":"Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years","volume":"34","author":"Ince","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.ejps.2019.105095_bib0022","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40262-013-0050-0","article-title":"A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults","volume":"52","author":"Ince","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ejps.2019.105095_bib0023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","article-title":"Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations","volume":"52","author":"Ince","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"8923","key":"10.1016\/j.ejps.2019.105095_bib0024","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(94)92085-0","article-title":"Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies","volume":"344","author":"Jacqz-Aigrain","year":"1994","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0026","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1023\/A:1018877803319","article-title":"Interrelationship between substrates and inhibitors of human cyp3a and P-glycoprotein","volume":"16","author":"Kim","year":"1999","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.ejps.2019.105095_bib0027","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-1033.1997.00625.x","article-title":"Expression of cyp3a in the human liver\u2013evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth","volume":"247","author":"Lacroix","year":"1997","journal-title":"Eur J Biochem"},{"issue":"13","key":"10.1016\/j.ejps.2019.105095_bib0028","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on hplc-ms\/ms","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem"},{"key":"10.1016\/j.ejps.2019.105095_bib0029","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0736-4679(97)00022-X","article-title":"Midazolam: a review of therapeutic uses and toxicity","volume":"15","author":"Nordt","year":"1997","journal-title":"J Emerg Med"},{"issue":"6","key":"10.1016\/j.ejps.2019.105095_bib0031","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/bja\/82.6.900","article-title":"Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro","volume":"82","author":"Oda","year":"1999","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ejps.2019.105095_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/309342","article-title":"Clinical pharmacology of midazolam in neonates and children: effect of disease-a review","volume":"2014","author":"Pacifici","year":"2014","journal-title":"Int J Pediatr"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"10.1016\/j.ejps.2019.105095_bib0034","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/00000542-200612000-00013","article-title":"Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery","volume":"105","author":"Peeters","year":"2006","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/adc.2007.119628","article-title":"Analgesia and sedation in critically ill children","volume":"93","author":"Playfor","year":"2008","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0036","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00000542-198503000-00017","article-title":"Midazolam: pharmacology and uses","volume":"62","author":"Reves","year":"1985","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.ejps.2019.105095_bib0037","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105095_bib0038","unstructured":"Summary of product characteristics of Midazolam 1\u202fmg\/ml solution for injection or infusion, available on: https:\/\/www.medicines.org.uk\/emc\/product\/6045\/smpc. Accessed Jun 2018."},{"issue":"6","key":"10.1016\/j.ejps.2019.105095_bib0039","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/138920012800840347","article-title":"Growing up with midazolam in the neonatal and pediatric intensive care","volume":"13","author":"Swart","year":"2012","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/j.ejps.2019.105095_bib0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/A:1023433502647","article-title":"Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate","volume":"20","author":"Tolle-Sander","year":"2003","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.ejps.2019.105095_bib0041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","article-title":"Inflammation and organ failure severely affect midazolam clearance in critically ill children","volume":"194","author":"Vet","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejps.2019.105095_bib0042","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fped.2016.00089","article-title":"Sedation in critically ill children with respiratory failure","volume":"4","author":"Vet","year":"2016","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ejps.2019.105095_bib0043","unstructured":"World Health Organisation (WHO) child growth standards, available on: http:\/\/www.who.int\/childgrowth\/standards\/weight_for_age\/en\/. Accessed Jun 2018."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:49:15Z","timestamp":1760528955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719303689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":43,"alternative-id":["S0928098719303689"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105095","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105095"}}